Not exact matches
For nearly two decades, gene therapy researchers have focused on delivering a gene carrying the code to
produce the deficient clotting factor in
hemophilia.
Scottish researchers took a similar approach to clone sheep that will
produce in their milk human factor IX protein, which is used to treat
hemophilia.
To verify that the process worked, the endothelial cells with the inversion - corrected genes were transplanted into F8 deficient mice (mice with
hemophilia A) and the mice started
producing the F8 clotting factor on their own, which essentially cured them of
hemophilia A.
Other genetic diseases include Tay - Sachs disease (damage to the gene for the enzyme hexosaminidase A leads to an accumulation of a chemical in the brain that destroys it), sickle cell anemia (improper coding of the gene that
produces hemoglobin),
hemophilia (lack of a gene for a blood - clotting factor) and muscular dystrophy (caused by a defective gene on the X chromosome).
Years after receiving a single dose of gene therapy, patients on the
hemophilia B trial continued to
produce their own clotting factor from the normal transferred gene with minimal side effects.
The resultant clones with functional FIX can then be screened for integration of the viral backbone in safe harbor regions and for its robust expression, subsequent to which they will be differentiated in vitro to the hepatic lineage, with a view to
producing a cell - based therapy for
hemophilia.